Clinical trials for medicines: modifying a clinical trial approval

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the requirements for modifying clinical trials under the Medicines for Human Use (Clinical Trials) Regulations 2004, which became fully effective on April 28, 2026. The regulatory framework requires trial sponsors to use a risk-based approach to categorize trial changes into three tiers: substantial modifications, modifications of an important detail, and minor modifications. Substantial modifications are divided into Route A, which requires a full 35-day review for changes impacting safety or data integrity, and Route B, which allows for a streamlined 14-day automatic approval for lower-risk changes. Modifications of an important detail require administrative notification, while minor changes only require internal record-keeping. Required actions for sponsors include utilizing the Integrated Research Application System (IRAS) for submissions, paying necessary fees, and documenting all justifications for modification categories. The MHRA monitors compliance through inspections and may audit Route B approvals. Failure to correctly categorize modifications or implement them without required approval can lead to regulatory invalidation. The guidance also outlines a formal appeals process through the Commission on Human Medicines for sponsors contesting unfavorable decisions.